Background and purpose: Breast cancer is the second leading cause of cancer death in women and the most common cancer causing liver metastases. Radiofrequency ablation (RFA) is a new method in treatment of liver metastases. This study was designed to evaluate the efficacy of RFA on liver metastatic breast tumors.
Materials and methods: In a randomized clinical trial, 52 patients with liver metastases from breast cancer who had less than 5 lesions < 5 cm enrolled. They were divided into two groups; an intervention group that received both chemotherapy and RFA and a control group who had only chemotherapy. Different variables were evaluated e.g. changes in lesion size, residual tumor status, and therapy complications. Data was analyzed in SPSS V20.  
Results: In a randomized clinical trial, 52 patients with liver metastases from breast cancer who had less than 5 lesions < 5 cm enrolled. They were divided into two groups; an intervention group that received both chemotherapy and RFA and a control group who had only chemotherapy. Different variables were evaluated e.g. changes in lesion size, residual tumor status, and therapy complications. Data was analyzed in SPSS V20.  
Conclusion: RFA was found as a safe and efficient method in treatment of liver metastases from breast carcinoma and showed a significant synergistic effect in patients under ingesting chemotherapy drugs.